News stories about Aileron Therapeutics (NASDAQ:ALRN) have been trending somewhat positive recently, Accern Sentiment reports. The research firm identifies negative and positive news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Aileron Therapeutics earned a news sentiment score of 0.15 on Accern’s scale. Accern also gave news stories about the company an impact score of 46.678556085583 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
ALRN has been the topic of a number of research analyst reports. Canaccord Genuity reissued a “buy” rating and set a $19.00 price objective on shares of Aileron Therapeutics in a report on Friday, August 11th. Bank of America Corporation initiated coverage on shares of Aileron Therapeutics in a report on Monday, July 24th. They set a “buy” rating and a $19.00 price objective on the stock. Jefferies Group LLC initiated coverage on shares of Aileron Therapeutics in a report on Monday, July 24th. They set a “buy” rating and a $20.00 price objective on the stock. Finally, William Blair initiated coverage on shares of Aileron Therapeutics in a report on Monday, July 24th. They set an “outperform” rating on the stock.
Shares of Aileron Therapeutics (NASDAQ:ALRN) opened at 11.42 on Friday. The company’s 50-day moving average is $12.67 and its 200-day moving average is $12.60. Aileron Therapeutics has a 12-month low of $10.37 and a 12-month high of $14.32. The stock’s market cap is $168.05 million.
In other Aileron Therapeutics news, insider Lilly Ventures Fund I. Llc acquired 250,000 shares of the firm’s stock in a transaction that occurred on Wednesday, July 5th. The stock was acquired at an average cost of $15.00 per share, for a total transaction of $3,750,000.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, major shareholder Cvf, Llc acquired 180,000 shares of the firm’s stock in a transaction that occurred on Wednesday, July 5th. The stock was acquired at an average price of $15.00 per share, with a total value of $2,700,000.00. The disclosure for this purchase can be found here. Over the last ninety days, insiders bought 696,667 shares of company stock valued at $10,450,005. 68.10% of the stock is currently owned by company insiders.
Aileron Therapeutics Company Profile
Aileron Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing a class of therapeutics called stapled peptides. It is also developing a pipeline of stapled peptide drugs across a range of therapeutic areas, including cancer, endocrine and metabolic diseases and inflammation.
Receive News & Ratings for Aileron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aileron Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
